Background: A broad literature base exists for measuring medication adherence to monotherapeutic regimens, but publications are less extensive for measuring adherence to multiple medications. Objectives: To identify and characterize the multiple medication adherence (MMA) methods used in the literature. Methods: A literature search was conducted using PubMed, PsycINFO, the International Pharmaceutical Abstracts, the Cumulative Index to Nursing and Allied Health Literature and the Cochrane Library databases on methods used to measure MMA published between January 1973 and May 2015. A two-step screening process was used; all abstracts were screened by pairs of researchers independently, followed by a full-text review identifying the method for calculating MMA. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed to conduct this systematic review. For studies that met the eligibility criteria, general study and adherence-specific characteristics and the number and type of MMA measurement methods were summarized. Results: The 147 studies that were included originated from 32 countries, in 13 disease states. Of these studies, 26 used proportion of days covered, 23 used medication possession ratio, and 72 used self-reported questionnaires (e.g., the Morisky Scale) to assess MMA. About 50% of the studies included more than one method for measuring MMA, and different variations of medication possession ratio and proportion of days covered were used for measuring MMA. Conclusions: There appears to be no standardized method to measure MMA. With an increasing prevalence of polypharmacy, more efforts should be directed toward constructing robust measures suitable to evaluate adherence to complex regimens. Future research to understand the validity and reliability of MMA measures and their effects on objective clinical outcomes is also needed.
Introduction
Medication nonadherence affects the health of individuals and influences the function of health care systems. 1 It has been shown to increase the risk of hospitalization, number of emergency department visits, and rate of mortality, 2 some of which may have been delayed, reduced, or avoided had patients remained adherent. On a global level, poor adherence also causes a financial burden on already scarce resources of health care systems. In the United States alone, the total cost associated with medication nonadherence has been estimated to be between $100 and $300 billion a year. 3 Accurately measuring medication adherence remains a clinical and research challenge. The proliferation of methods in recent years underlines the importance of measuring medication adherence not only for identifying barriers to medication-taking but also for developing interventions to address these barriers. Ensuring accurate measurement of medication adherence can help improve patients' health outcomes and reduce health care spending.
Most publications for measuring medication adherence and associating adherence with positive outcomes have focused on the use of a single medication or monotherapeutic regimen. 4e6 Some methods include directly observing patients consuming medications, pill counting, monitoring through electronic pill dispensers, and measuring adherence through outcomes such as serum drug concentration levels. Other medication adherence measurement methods pertain to clinical and administrative claims data, registries, patient and provider surveys, self-report questionnaires and scales, patient diaries, electronic and paper medical records, charts, and pharmacy records. 7, 8 These methods
include several measures such as medication possession ratio (MPR), proportion of days covered (PDC), time to discontinuation, persistence rate, medication gaps, composite adherence score, and the Morisky Medication Adherence Scale (MMAS). 8, 9 When patients' medication regimens involve multiple medications (polypharmacy) prescribed for the same or multiple conditions, the challenge of accurately measuring medication adherence is compounded by the complexity that arises from intermixing the dosing and timing schedules of each drug as their combined effects manifest into a single treatment regimen. The prevalence of polypharmacy is becoming increasingly common as more medications are developed to manage diseases, particularly chronic conditions. More than 30% of the global population has more than five acute or chronic conditions requiring multiple medications 10 ; as for the United States, approximately 50% of the adults have one or more chronic condition, whereas one in four has two or more chronic conditions. 11 This percentage is expected to increase as life expectancy increases. Therefore, it is crucial to understand how the methods of measuring medication adherence in monotherapy would translate into polypharmacy. Moreover, as the proportion of people with multiple medical conditions increases, treatment regimens are likely to become more complex with a greater variety of therapeutic and pharmacologic options available. Thus, multiple medication adherence (MMA) methods need to account for such complexity in regimens involved in polypharmacy.
To date, a systematic review of the literature that describes how MMA has been measured has not been performed. Therefore, there is a need to review and describe methods used to examine MMA. This systematic review aimed to identify and compare the measures used for MMA found in the literature. In addition, this review will explore the extent of use of MMA measures in various disease conditions.
Methods
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines to conduct and report this systematic review. 12 
Study Selection Criteria
We selected studies that included participants who used two or more concurrent medications for any acute or chronic medical condition(s). No limitations were applied to the selection of studies based on any specific intervention, control treatment, study type, or the characteristics of the study population. Only studies reporting any measure assessing MMA for a medical condition were included. Studies were excluded if they did not assess MMA. Hence, studies that were limited to measuring adherence to a single medication including fixed-dose combination medications were not included. If studies did not mention the evaluation method for medication adherence, they were considered ineligible. Studies evaluating adherence to guidelines or adherence to nonpharmacological treatment (e.g., diet and exercise) were excluded. Randomized controlled trials, observational studies (including retrospective, prospective, and cross-sectional studies), and other experimental studies examining and reporting MMA were included. Studies that reported an algorithm for testing or validating MMA measures were also considered. Conference proceedings, reviews, dissertations, book chapters, case studies, editorials, and letters were excluded because they were not considered as original research. In addition, studies were selected only if they were initially identified from a database search or a subsequent manual review of citations in selected articles. The criteria were applied throughout the selection process, including the initial selection, which consisted of a broad automated literature search of selected information about published articles and a manual review of their references, a manual selection process that included an initial review of the abstracts, and a final review of the full text.
Literature Search
Initial selection of the studies began with a literature search using PubMed, PsycINFO, the International Pharmaceutical Abstracts (IPA), the Cumulative Index to Nursing and Allied Health Literature (CINAHL), and the Cochrane Library databases on studies published between January 1, 1973, and May 13, 2015. The search was limited to only those studies that involved humans and were reported in English. While undertaking this systematic review, we did not distinguish between medication adherence and persistence, although the two terms have been used for two slightly different aspects of medication-taking behavior. Medication adherence or compliance typically refers to "the extent to which the patient acts in accordance with the prescribed interval and dose of a dosing interval," whereas medication persistence is defined as "the duration of time from medication initiation to discontinuation". 13 Although authors of the studies included in our systematic review may not have distinguished between adherence and persistence, the exact formula used to measure them was recorded whenever available. The search strategy used both Medical Subject Headings terms and text words to create search strings for adherence, polypharmacy, measurement methods, and multiple disease conditions. Some of the search terms included "adherence," "compliance," "persistence," "polypharmacy," "multiple therapies," "overlapping prescriptions," "Morisky Scale," "proportion of days covered," "medication possession ratio," "comorbidity," and "multicomorbidity." The exact search strategy used for each database is given in Appendix 1 in Supplemental Materials found at https://doi.org/10.1016/j.jval.2018.08.006. Additional relevant studies were obtained by manual searches of the reference lists of initially selected studies. Because this initial selection searched multiple electronic databases, this step ended with the consolidation of citations from all sources into a unique listing.
Selection of Studies
The citations were investigated during the initial selection process, which included an automated literature search and a manual search. The consolidated listing was divided evenly among seven pairs of reviewers to complete the manual screening process. During the initial review, each reviewer independently assessed the content from titles and abstracts of assigned articles against the common eligibility and predefined selection criteria to decide whether there was enough information to warrant a request for the full text of an article for final review. During the final review, each reviewer again independently evaluated the full text of assigned articles against the inclusion criteria, extracting predetermined data elements in the standardized template. For both the initial and final reviews, the pairs shared their independently gathered data and resolved any disagreements by consensus, with additional consultations with a study lead if necessary. The selection process was documented with a Preferred Reporting Items for Systematic Reviews and MetaAnalyses flowchart.
Data Extraction
Data extraction was done by seven pairs of reviewers, with each reviewer independently extracting data elements into the standardized template developed by the research team. The data elements in the standardized template included general study and adherence-specific characteristics. The general characteristics included type of study design; region where the study was conducted; sample size; publication year; participant's age, sex, and ethnicity; study period; diseases investigated; and types and names of medications included in the study. The adherencespecific characteristics included the terms used for medication adherence, the data sources, the nature (e.g., clinical or nonclinical in nature) of the metric, the number of measurement methods, and description of the method of measurement of adherence. To simplify reporting of data collection method and measurement methods, we used the term "administrative data" to cover similar terms when some others may have used them to refer to the same collection method. It is the term we used to cover administrative claims, pharmacy claims data, prescription refill records, administrative pharmacy records, medical claims, and electronic medical records. The term "self-report" was used when a citation may have specifically stated a measurement method as questionnaire, survey, collaterally reported (e.g., nurse/physician/ caregiver), or having used an instrument.
Data Analysis
Descriptive statistics on study designs, sample size, disease conditions, specific adherence formulas, and other characteristics were reported. In addition, the number and percentage of studies using unique MMA measurements were summarized. The authors recognize the importance of including robust high-quality articles in this systematic literature review. Nevertheless, because the purpose was to identify specific methods used to measure MMA, assessment of methodological quality or risk of bias was outside the scope of this review and therefore was not reported.
Results

Literature Search
The literature search resulted in 1706 records across the five databases with an additional 8 being identified through the manual search of the reference lists of the initially selected articles and a discussion among reviewers at each step of the review (Fig. 1) . After removing duplicates, we screened titles and abstracts of 1382 records, resulting in 301 potentially eligible articles for fulltext review. After reviewing relevant full texts, 154 articles were excluded, mainly because either the evaluation method of medication adherence was not described (n ¼ 53) or the study did not assess MMA (n ¼ 84). Data were extracted from the remaining 147 studies for this analysis, the first of which was published in 1990 and almost 58% being published in 2010 or later. In the three decades since the first publication, 4 were published in the 1990s, 57 in the 2000s, and 85 between 2010 and 2015. No articles were published between 1970 and 1989.
Study Characteristics
The general characteristics of included articles are presented in Table 2 . The details include study design, sample size, country, diseases studied, methods used to collect data to measure adherence, and methods of calculating adherence for multiple medications.
MMA Measures
All included studies investigated medication adherence to more than one medication ( 
Utilization-Based MMA Measures
In studies that used electronic data records, several different measures were applied for calculating adherence, including variations of MPR, PDC, and missing days or doses calculations (Table 4) . Formulas for derivation of MPR and PDC varied between studies; 9 different versions were used for MPR and 10 were used for PDC (Table 4) .
Self-Reported MMA Measures
More than half the studies (n ¼ 78, 53.1%) used a self-report method for measuring MMA ( Table 3 ). The most commonly applied self-reported measure was the MMAS (4-/8-/9-item version), which was applied in 21 studies (14.3%) ( Table 4) .
MMA Measures and Disease Conditions
Application of adherence measures varied across disorders. For cardiovascular disorders, PDC was the most commonly used adherence measure; nevertheless, for sexually transmitted disorders (e.g., HIV/AIDS), self-reported methods were preferred (Fig. 2) .
Discussion
This systematic literature review summarizes the MMA measures used in articles published from January 1, 1973, to May 13, 2015. We found that the first article on MMA was published in 1990 and 6 as per our knowledge, there is no systematic review that exclusively assesses MMA measures used in the literature. Previous systematic reviews reported MMA measures in the context of adherence-improving interventions, but none addressed measurement of MMA as their primary focus. Measures based on patient self-report could be simple, inexpensive, and straightforward and therefore can be conveniently administered in research and clinical practice settings. This view potentially explains why more than 50% of the studies included MMA measures based on self-report. Within the self-reported measures, there were 32 different MMA measures, with MMAS being used in the largest number of studies (21 studies, or 14.3%). The dominance of MMAS as an MMA measure is perhaps not surprising given that the MMAS is a well-established measure and because its concurrent and predictive validities have been well documented. 9, 22 It is also important to note that some selfreported measures are designed for specific diseases. For example, we found multiple HIV/AIDS-specific MMA measures including the Adult AIDS Clinical Trial Group Adherence to Combination Therapy Guide, Community Programs for Clinical Research on AIDS Adherence Form, and Swedish HIV Cohort StudydAdherence Questionnaire. As found by Nguyen et al., 23 the underlying motivations behind the use of different self-reported measures are whether the goal of the study is to shed light on medication-taking behavior, to understand barriers to medication adherence, and to elicit patients' beliefs about medicine. Nevertheless, medication adherence methods based on self-report are not without criticism. Many authors have identified that selfreported methods have the potential of over-reporting adherence or failing to disclose nonadherence due to recall bias, missing data, social desirability concerns, and faults in selfobservation. 24e26 Another criticism identified in our literature review is the large volume of self-reported measures used, which leads to difficulties in making comparisons between studies. Indeed, research has shown poor agreement between selfreported measures of adherence. 27e30 Only a few studies combined self-reported measures with database measures such as MPR and PDC. In addition, there was a difference in verbiage used to solicit self-reported adherence. Medication adherence is a complex behavior involving initiation of therapy, implementing a dosing regimen and persisting with treatment. 31 These separate facets of adherence behavior are not currently captured in selfreported measures. It is also often not clear what aspect of adherence behavior is captured in self-reported measures. Like self-reported measures, MPR-and PDC-based MMA measures also had multiple variants. For example, there were 9 MPRbased submeasures and 10 PDC-based submeasures. There is a subtle distinction between operationalizing PDC and MPR, where the PDC numerator is the sum of covered days and the numerator for MPR is the sum of days supplied. In addition, 24 (16.3%) studies calculated some disparate MMA measures. The wide variation in MPR-and PDC-based MMA measures could potentially be attributed to study design (e.g., retrospective vs. prospective study), data availability, potential subjectivity in opting for one specific method versus others, clinical judgment, or the complexity of the underlying treatment patterns such as titration, augmentation, 6 and switching. Different adherence definitions have been shown to lead to qualitatively different conclusions. As mentioned by Choudhry et al., 32 the choice of a specific MMA measure might hinge on why adherence is being evaluated. The lack of standardization in MMA measures found in the literature often prevents conducting meta-analyses in which multiple studies can be pooled to assess the effect of interventions for medication adherence. 33 Future research is needed to assess the appropriateness of the derivations of measurements outlined in the previous sections because this was outside the scope of the present review and therefore not evaluated. The existence of heterogeneous MMA measures renders comparison of studies a challenge, suggesting that simulation or other follow-up studies need to be conducted to assess the existing measures in terms of their ability to measure true MMA. Quantifying the effect each measure has on true MMA may enable us to factor in the underestimation or overestimation of bias each method has on MMA measurement. The importance of such standardized MMA measures will increase in coming years because approximately one in every four persons in the United States has more than two chronic conditions. 11 In addition, single conditions are also commonly being treated with multiple medications. It has been shown that medication adherence not only improves clinical outcomes but also leads to decrease in avoidable adverse events and health care utilization, resulting in lower costs. 34e37 In addition, having the ability to estimate such standardized MMA measures would help identify at-risk patient populations in real time, which in turn can help deploy adherence-improving interventions by health systems including health insurance or prescription drug plans. 38, 39 Our review also underscores the need for the pharmacoeconomics and outcomes research community to develop a checklist or guidelines with regard to the minimum reporting criteria involving MMA studies similar to Peterson et al., 40 who focused primarily on adherence to monotherapy. For example, a substantial number of studies (87, or 57.6%) did not report the number of medications upon which the reported MMA measure was based. Such studies then become very difficult to replicate using the same or other data, thereby making them redundant for any policymaking guidelines. A checklist would ensure that a certain minimum quality is met and maintained across all future studies of MMA. We also found that the prevalence of MMA measures was higher in some specific disease groups. For example, 43 (29.2%) studies pertained to cardiovascular disease area, whereas 45 (30.6%), 20 (13.6%), and 14 (9.5%) studies were in the areas of HIV/ AIDS, metabolic diseases, and mental health conditions, respectively. It can be speculated that this pattern could potentially be an artefact of how these or related diseases manifest in patients often requiring combination therapy, which is why the prevalence of MMA measures in these disease areas seems to be higher than in others. 41 In terms of specific MMA methods used, MPR, PDC, and patient-reported outcome questionnaires were used somewhat in equal numbers in cardiovascular diseases, whereas patient-reported outcome and other self-reported MMA measures dominated mental health conditions potentially because of convenience of administering measures based on self-report to patients with mental health issues. This study has several limitations. First, this systematic review considered only articles published in English. Second, the systematic review profiled the MMA measures used for more than four decades; nevertheless, the study was not designed to find out the best MMA measures, and therefore cannot recommend one measure over another. Limitations exist with each of the measures of medication adherence, and some are well known. For instance, MPR as commonly calculated has been reported to overestimate adherence by considering overlapping days of MMA, multiple medication adherence. * Some studies included patients with multiple disease conditions. y Some studies included more than one adherence data collection method. V A L U E I N H E A L T H 2 2 ( 2 0 1 9 ) 1 3 9 e1 5 6 Average of P days of supply per medication/study period 4 (2.7) P days of supply for all medications/study period 4 (2.7) P days of supply for any medication/study period 2 (1.4) Average of ( P days of supply/days between last prescription and first prescription) per medication; supply obtained in the last fill was excluded 2 (1.4) Average of ( P days of supply/days between last prescription and first prescription) per medication 1 (0.7) P days of supply for multiple medications/(days between last prescription and first prescription þ days of supply for last fill) 1 (0.7) P days of supply for all medications/(days between last prescription and first prescription þ days of supply for last fill) 1 (0.7) P tablets dispensed/ P tablets recommended or prescribed 1 (0.7) Weighted average of ( P days for supply/(days for which medication was needed e days spent in hospital)) per medication 1 (0.7)
Unclear how MPR to multiple medications was calculated 6 (4.1) PDC: In general, the numerator is the sum of days covered by a medication (or combination of medications for MMA) and the denominator is the length of the study period. Most studies have at least one variant for either or both the numerator and denominator
(17.7)
Overlap variant (PDC overlap): The numerator counts only those days on which more than one drug/all drugs were available/accessible/prescribed or otherwise overlapping
(8.2)
P days covered for all medications/study period 10 (6.8) P days covered for at least a given number of medications/study period 1 (0.7) P number of days the patient was prescribed index combination therapy/study period 1 (0.7) Any drug variant PDC: The numerator includes days covered for any of the polytherapy combinations 2 (1.4) The smallest number of days covered by any index medication/study period 1 (0.7) continued on next page Covered minutes per day ¼ [(1440 min À uncovered minutes)/1440 min] Â 100 1 (0.7) Daily patient possession ratio ¼ look at each day in the observation period separately; determine how many medications are available, set a score between 0 (no medication available) and 1 (all medications available) weighted by the number of medications to be taken each day, resulting in daily scores indicating the proportion of medications available for each day; sum the scores and divide by the number of days in the observation period to obtain the proportion of all medications available for daily use
Medication total ¼ P supply of pills dispensed/number of days elapsed 1 (0.7) Overall pill count adherence score represented the mean pill count adherence across all prescribed medications 1 (0.7) Proportion of medications taken during the past week 1 (0.7) (Number of medications taken/number of medications prescribed) Â 100 over a 7-d period 1 (0.7) P days pills taken/ P potential medications 1 (0.7) Number of refills obtained over the prescribed number 1 (0.7) P days supplied for at least one medication/study period (not defined as MPR/PDC) 1 (0.7) P doses taken within ±3 h of the median time/ P doses prescribed over study period 1 (0.7) Unclear how adherence to multiple medications was calculated 2 (1. supply even for monopharmacotherapy. Even though PDC includes an adjustment for overlapping days' supply of medication, it ignores the situations of early filling of prescriptions and stockpiling. Self-reported methods have been reported to overestimate adherence as compared with other measurement methods and possess less sensitivity. Follow-up simulation as well as validation studies that compare the performance of these MMA methods need to be conducted. Third, our review relied on what was reported by the authors, even though the terms they associated with their metrics may be inconsistent with more recently standardized definitions for the same terms and methods. For instance, in more than half the studies identified as using PDC, authors described the PDC numerator as the summation of days' supply when, operationally, only MPR is the summation of days' supply and PDC is the summation of days covered. Overlooking this subtle distinction between methods means the terms were misapplied or the terms had not been standardized at the time of publication or the authors did not differentiate the subtle differences. Similarly, most of the MMA studies seemed to require at least two fills for the medications under consideration. This is not a requirement for the measure, but rather a variant that potentially misses nonadherence among patients who stop taking the medication after their first fill. 33, 41, 42 Fourth, although we searched five large databases for relevant articles, our selection of search terms may not be exhaustive enough to rule out the possibility of missing studies despite reference mining. Fifth, the study inclusion/exclusion criteria did not require assessment of the quality of studies, which might have resulted in inclusion of studies with poor research methodology marked by high risks of bias, and concerns about the measures used. Finally, this review may have missed publications from last 2 years. Further research may evaluate the relationship between number of medications and adherence rate and the differences in medication adherence rate between medications that treat symptoms and those whose effects are not necessarily apparent to patients.
Conclusions
Our findings suggest that there is no criterion standard available to measure MMA. Furthermore, there is a lack of agreement between researchers on how to use a specific existing measure to calculate MMA. The choice of an appropriate method or a combination of methods was found to depend on the study setting, availability of data and other resources, and disease type. With increasing burden of comorbidities and prevalence of polypharmacy, more efforts should be directed toward constructing robust measures that can be used to evaluate adherence to complex regimens. This review also demonstrates that the researchers should undertake endeavors to formulate clear operationalization of MMA for a single disease as well as multiple diseases. Furthermore, it would be beneficial for future researchers to use multiple instruments simultaneously to validate MMA from various perspectives (e.g., self-report and administrative databases). And finally, the need for further research to understand the validity and reliability of all existing measures to evaluate MMA and their effects on objective clinical outcomes is paramount.
